+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effects of different extents of lymph node dissection performed alongside radical prostatectomy in men with localized or locally advanced prostate cancer. This randomized controlled study aims to compare outcomes between limited or no lymph node removal and extended lymph node removal during surgery. The goal is to optimize the volume of lymph node removal in these patients to better understand its impact on long-term survival and complications. Participants will be randomly assigned to receive either radical prostatectomy with limited or no lymph node dissection or radical prostatectomy with extended lymph node dissection. The extent of lymph node removal depends on the patients prostate cancer risk category, with extended dissection including more lymph nodes for higher-risk patients. The study tracks surgical details such as blood loss and surgery duration, as well as postoperative complications and length of hospital stay. During the study, participants will be followed for up to 5 to 7 years after surgery. Researchers will monitor metastasis-free survival as the primary outcome, along with secondary outcomes including biochemical recurrence-free survival, prostate cancer-specific survival, overall survival, and perioperative events. Follow-up visits will assess recovery, complications, and hospital stay length. The study involves careful evaluation of long-term cancer outcomes and surgical safety in men undergoing radical prostatectomy.

Age: 18Years +MALEPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the use of academic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory large B-cell lymphoma LBCL. This observational study aims to assess the effectiveness and safety of a CAR-T cell product made using a lentiviral vector encoding the anti-CD19 CAR in a real-world clinical setting. The study is conducted at the NN Alexandrov National Cancer Centre of Belarus and focuses on patients who have already received prior anti-tumor therapy. The academic CAR-T cell therapy studied encodes an anti-CD19 CAR construct with a specific antibody fragment FMC63 linked to several components for activation and safety, including a safety switch marker. This therapy is administered to patients with confirmed CD19 expression in their tumor tissue. The study observes the treatment as it is given in routine practice without altering the approach. Participants are monitored for response 30 days after CAR-T infusion, focusing on the overall response rate. Secondary outcomes include event-free survival and overall survival measured over five years. Patient evaluations include confirming eligibility based on disease status and prior treatment history. The study tracks safety and outcomes over a long-term period up to five years, with participation lasting from treatment through extended follow-up.

Age: 18Years - 80YearsAll Genders
1 location